Matthew Pauls
Chairman & CEOMr. Matthew Pauls, J.D. M.B.A. also known as Matt, serves as Director of Atsena Therapeutics, Inc. since June 2026. He is Director of Palvella Therapeutics, Inc. from June 29, 2026. Mr. Pauls is Independent Director of Pelthos Therapeutics Inc. from July 1, 2025. He is Director at NVN Liquidation Inc. He serves as Director of Soleno Therapeutics, Inc. since August 15, 2023 and is its Lead Independent Director aince August 2024. He serves as Chief Executive Officer at Savara Inc. since December 8, 2020, serves as Chairman of the Board since September 11, 2020 and serves as Member of the Board since April 2017. He served as Interim Chief Executive Officer at Savara Inc. since September 11, 2020 until December 8, 2020. He served as an Independent Director at Savara Inc. (formerly Mast Therapeutics, Inc.), since October 2015 until September 11, 2020. Mr. Pauls had been Independent Director of Zyla Life Sciences since February 2019 from January 2019 until its merger with Assertio Therapeutics, Incorporated in May2020. He has been the Chief Executive Officer and President of Cortendo AB since August 2014. Mr. Pauls has been Director of Egalet Corporation since January 31, 2019. He served as the Chief Executive Officer and President of Strongbridge Biopharma plc since August 25, 2014 until November 1, 2019. Prior to joining Strongbridge Biopharma in 2014, Mr. Pauls served as the Chief Commercial Officer of Insmed Incorporated from April 1, 2013 to August 2014. In this role, he built out the global commercial strategy and organization and led the global technical operations efforts. He played a key role in investor interactions and financings. He has experience in the pharmaceutical industry, including senior-level leadership positions, with an emphasis on general management, global product launches, commercial operations, business development, clinical development and technical operations at leading pharmaceutical companies including Shire Pharmaceuticals since 2007 until March 2013, Bristol-Myers Squibb and Johnson & Johnson. Prior to Shire, from 1997 to 2007 he served with Bristol-Myers Squibb as Senior Director of Payor Marketing for their Neuroscience Franchise. Mr. Pauls spent eight years with Johnson & Johnson in positions of increasing responsibility in their CNS Franchise, including Global Commercial Leader and Director of Strategic Marketing. He was with Shire Pharmaceuticals, served as Senior Vice President and Head of Global Commercial Operations, Shire Regenerative Medicine. In this role, he led the global commercial function of a business unit with a staff of approximately 300 including a 200-person U.S. sales team. He served as Vice President, Product General Manager, Shire Specialty Pharmaceuticals Behavioral Health Business Unit, where he had P&L responsibility for Vyvanse(R) in the U.S. and Intuniv(R) globally. He began his career as a pharmaceutical sales representative for Carter Wallace. He served as the Chairman of the Board at Mast Therapeutics, Inc from October 2015 to April 2017. Previously, Mr. Pauls was the founder of Spartan Biopharma Insights, LLC from December 2019 to September 2020. He has been a Director of Cortendo AB since September 2015 and Mast Therapeutics, Inc. since October 2015. He served as a Director of Strongbridge Biopharma plc since September 4, 2015 until November 1, 2019. Mr. Pauls is a volunteer board member of the Pennington School in Pennington, New Jersey and the Boys & Girls Clubs of Philadelphia. Mr. Pauls has served on the board of directors of the privately held companies Amplo Biotechnology, Inc. Mr. Pauls holds BS and MBA degrees from Central Michigan University and a JD from Michigan State University College of Law.
Positions
- Company NameSavara Inc.Stock CodeSVRAPositionChairman & CEOColleagues
- MPMatthew PaulsChairman & CEO
- RMRobert Matthew LutzCOO & CFO
- YWYasmine WasfiChief Medical Officer
- KMKate McCabeChief Legal Officer
- MCMegan CarpenterChief People Officer
- NCNevan Charles ElamIndependent Director
- JSJoseph S. McCrackenLead Independent Director
- DADavid A. RamsayIndependent Director
- RJRichard J. HawkinsIndependent Director
- Company NamePelthos Therapeutics Inc.Stock CodePTHSPositionIndependent Director
